Prosdex formed part of the UK Prostate Cancer Risk Management Programme strategy, led by the National Cancer Screening Programmes, which had, at its heart, the concept of informed choice in PSA testing [4]. The gene discussed is KLK3; the disease is prostate carcinoma.